Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

AbbVie Inc

ABBV
$213.76 (+ $3.86 + 1.84%)
Last updated: Previous Close (2026-05-19)
ABBV Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS00287Y1091
Market Price213.76
Dividend Yield 3.31%
Dividend Growth
1Y +33.23%
3Y +12.06%
5Y +12.49%
10YN/A
Annual Dividend 8.38
Latest Payout ($)1.73
Latest Payout Date2026-02-17
Dividend FrequencyQuarterly
P/E Ratio103.82
EPS1.32
Market Cap$394.4B
Book Value-1.5
Price to Book-153.037
Beta-0.38
52w High244.81
52w Low176.57
Next Earnings DateN/A
About the Company
AbbVie Inc. is a research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Headquartered in North Chicago, Illinois, and founded in 2012 as a spin-off from Abbott Laboratories, it employs approximately 55,000 people and operates primarily in the pharmaceuticals and biotechnology sector. Key products include Humira, a leading treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis; Skyrizi and Rinvoq for immunology indications like plaque psoriasis and ulcerative colitis; Imbruvica for blood cancers; and Botox for neurological conditions and aesthetics following the 2020 Allergan acquisition. AbbVie Inc. maintains a robust pipeline addressing immunology, oncology, neuroscience, and other therapeutic areas, with recent advancements in treatments for essential tremor and kidney disease. Its global presence underscores its significant role in advancing healthcare solutions and contributing to the biopharmaceutical industry's growth.
Price History
Latest News for ABBV
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff”
We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. AbbVie Inc. (NYSE:ABBV) is one of the stocks discussed by Jim Cramer. Pharmaceutical firm AbbVie Inc. (NYSE:ABBV)’s shares are up by 11% over the past year and are down by 9% year-to-date. Evercore ISI was out with optimistic coverage […]
2 Cash-Producing Stocks to Research Further and 1 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc. (NYSE:ABBV) received a rating update from Evercore ISI on May 4, with the firm lifting the price target on the stock to $236 from $232 while maintaining an Outperform rating on the shares. The company also announced […]
Top Stock Reports for NVIDIA, Mastercard & AbbVie
NVIDIA, Mastercard and AbbVie headline Zacks' top stock reports, with AI growth, payment trends and drug launches in focus.